Zymeworks BC Inc (NASDAQ:ZYME)’s traded shares stood at 0.32 million during the last session, with the company’s beta value hitting 1.09. At the close of trading, the stock’s price was $13.88, to imply a decrease of -0.79% or -$0.11 in intraday trading. The ZYME share’s 52-week high remains $17.70, putting it -27.52% down since that peak but still an impressive 42.58% since price per share fell to its 52-week low of $7.97. The company has a valuation of $963.94M, with an average of 0.56 million shares in intraday trading volume over the past 10 days and average of 515.58K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Zymeworks BC Inc (ZYME), translating to a mean rating of 1.50. Of 4 analyst(s) looking at the stock, 0 analyst(s) give ZYME a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.09.
Zymeworks BC Inc (NASDAQ:ZYME) trade information
After registering a -0.79% downside in the last session, Zymeworks BC Inc (ZYME) has traded red over the past five days. The 5-day price performance for the stock is 4.99%, and 0.80% over 30 days. With these gigs, the year-to-date price performance is -5.19%. Short interest in Zymeworks BC Inc (NASDAQ:ZYME) saw shorts transact 4.15 million shares and set a 8.11 days time to cover.
The extremes give us $12 and $28 for target low and target high price respectively. As such, ZYME has been trading -101.73% off suggested target high and 13.54% from its likely low.
Zymeworks BC Inc (ZYME) estimates and forecasts
Looking at statistics comparing Zymeworks BC Inc share performance against respective industry, we note that the company has underperformed competitors. Zymeworks BC Inc (ZYME) shares are 41.49% up over the last 6 months, with its year-to-date growth rate lower than industry average at 7.56% against 16.60%. The rating firms project that company’s revenue will grow 17.71% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is 45.2M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 18.5M.Earnings reports from the last fiscal year show that sales brought in 16.93M and 10.03M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 167.02% before jumping 84.45% in the following quarter.
ZYME Dividends
Zymeworks BC Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Zymeworks BC Inc (NASDAQ:ZYME)’s Major holders
Zymeworks BC Inc insiders hold 0.08% of total outstanding shares, with institutional holders owning 103.27% of the shares at 103.35% float percentage. In total, 103.27% institutions holds shares in the company.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Zymeworks BC Inc (ZYME) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 2.24 shares. This is just over 3.55% of the total shares, with a market valuation of $31.05 million. Data from the same date shows that the other fund manager holds a little less at 1.42, or 2.26% of the shares, all valued at about 19.75 million.
